LoQus23 are discovering oral small molecule therapies targeting aberrant DNA mismatch repair to effectively treat Huntington’s and other triplet repeat diseases.
Location: United Kingdom
Employees: 1-10
Total raised: $61.86M
Investors 1
| Date | Name | Website |
| 19.05.2025 | Forbion | forbion.co... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 04.10.2024 | Series A | $46.5M | - |
| 25.11.2021 | Seed | $15.36M | - |
Mentions in press and media 9
| Date | Title | Description |
| 06.01.2026 | LoQus23 Therapeutics nominates LQT-23 as first-in-class, oral drug candidate for Huntington’s Disease | Cambridge, UK, 6 January 2026 – LoQus23 Therapeutics Ltd (“LoQus23”), a biotechnology company investigating small molecule drugs that could stop the pathogenic triplet expansion that is the cause and driver of Huntington’s Disease (HD), myo... |
| 18.02.2025 | LoQus23 Therapeutics appoints Cyrus Mozayeni MD to Chair of the Board of Directors | Cambridge, UK, 18 February 2025 – LoQus23 Therapeutics Ltd (“LoQus23”), a private biotechnology company investigating small molecule drugs that could stop the pathogenic triplet expansion that is the cause and driver of Huntington’s Disease... |
| 18.02.2025 | LoQus23 Therapeutics appoints Cyrus Mozayeni MD to Chair of the Board of Directors | • Dr Mozayeni brings deep experience in biotech corporate strategy and business development • Appointment follows successful £35 million Series A fundraise at the end of 2024 to take its MSH3 inhibitors to treat Huntington’s disease into th... |
| 04.10.2024 | LoQus23 Therapeutics: £35 Million (Series A) Secured To Advance Small Molecule Somatic Expansion Inhibition Therapy | LoQus23 Therapeutics, a private biotechnology company investigating small molecule drugs that could stop DNA instability and slow neurodegeneration in Huntington’s Disease, myotonic dystrophy type 1, and similar triplet repeat expansion dis... |
| 02.10.2024 | LoQus23 Therapeutics Raises £35M in Series A financing | LoQus23 Therapeutics, a Cambridge, UK-based private biotechnology company investigating small molecule drugs, raised £35M in Series A funding. The round was led by Forbion, alongside existing investors SV Health Investors’ Dementia Discover... |
| 02.10.2024 | LoQus23 Therapeutics announces £35 million (c.$43 million) Series A financing to advance its small molecule somatic expansion inhibition therapy for Huntington's disease | Cambridge, UK, 2 October 2024 – LoQus23 Therapeutics Ltd (“LoQus23”), a private biotechnology company investigating small molecule drugs that could stop DNA instability and slow neurodegeneration in Huntington’s Disease, myotonic dystrophy ... |
| 25.11.2021 | LoQus23 Therapeutics Raises £7M in Seed Financing | LoQus23 Therapeutics Ltd, a Cambridge, UK-based company discovering small molecule therapies that target aberrant DNA mismatch repair (MMR) to treat Huntington’s and other triplet repeat diseases (TRDs), closed a £7m extended seed funding r... |
| 23.11.2021 | LoQus23 Therapeutics exits stealth with £11.5 million seed financing from the Dementia Discovery Fund and Novartis Venture Fund | - Company targets DNA mismatch repair pathways to slow neurodegeneration in Huntington's Disease and other triplet repeat disorders |
| - | LOQUS23 THERAPEUTICS | “LoQus23 Therapeutics – Stopping DNA instability; Slowing neurodegenerative disease” |